Barriers to treatment of hepatitis C in HIV/HCV-coinfected adults with alcohol problems

Alcoholism: Clinical and Experimental Research

Volumn 30, Issue 9, 2006, Pages 1520-1526

  Nunes, David ^a,e   Saitz, Richard ^a,c   Libman, Howard ^b   Cheng, Debbie M ^c   Vidaver, John ^d   Samet, Jeffrey H ^a,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d DM STAT Inc   (United States)

^e BOSTON MEDICAL CENTER   (United States)

Author keywords

Alcohol; Hepatitis C; HIV; Interferon

Indexed keywords

ANTIRETROVIRUS AGENT; INTERFERON; VIRUS RNA;

ADULT; AGED; ALCOHOL ABUSE; ARTICLE; CD4 LYMPHOCYTE COUNT; COMORBIDITY; DEPRESSION; DRUG ABUSE; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SUICIDAL IDEATION; TREATMENT CONTRAINDICATION;

ADULT; AGED; ALCOHOLISM; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON TYPE I, RECOMBINANT; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS;

HEPATITIS C VIRUS;

EID: 33747692257     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2006.00183.x     Document Type: Article

References (50)

1. Adeyemi OM, Jensen D, Attar B, Ghaoui R, Gallagher M, Wolen D, Cotler SJ (2004) Hepatitis C treatment eligibility in an urban population with and without HIV coinfection. AIDS Patient Care STDS 18:239-245.
2. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D (2001) Treatment of hepatitis C infection in injection drug users. Hepatology 34:188-193.
3. Bhattacharya R, Shuhart MC (2003) Hepatitis C and alcohol: interactions, outcomes, and implications. J Clin Gastroenterol 36:242-252.
4. Bini EJ, Brau N, Currie S, Shen H, Anand BS, Hu KQ, Jeffers L, Ho SB, Johnson D, Schmidt WN, King P, Cheung R, Morgan TR, Awad J, Pedrosa M, Chang KM, Aytaman A, Simon F, Hagedorn C, Moseley R, Ahmad J, Mendenhall C, Waters B, Strader D, Sasaki AW, Rossi S, Wright TL (2005) Prospective multicenter study of eligibility for antiviral therapy among 4084 U. S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 100:1772-1779.
5. Blackard JT, Yang Y, Bordoni P, Sherman KE, Chung RT (2004) Hepatitis C virus (HCV) diversity in HIV-HCV-coinfected subjects initiating highly active antiretroviral therapy. J Infect Dis 189:1472-1481.
6. Buchsbaum DG, Buchanan RG, Centor RM, Schnoll SH, Lawton MJ (1991) Screening for alcohol abuse using CAGE scores and likelihood ratios. Ann Intern Med 115:774-777.
7. Burack JH, Barrett DC, Stall RD, Chesney MA, Ekstrand ML, Coates TJ (1993) Depressive symptoms and CD4 lymphocyte decline among HIV-infected men. JAMA 270:2568-2573.
8. Campbell JV, Hagan H, Latka MH, Garfein RS, Golub ET, Coady MH, Thomas DL, Strathdee SA (2006) High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities. Drug Alcohol Depend 81:259-265.
9. Carlos Martin J, Castilla J, Lopez M, Arranz R, Gonzalez-Lahoz J, Soriano V (2004) Impact of chronic hepatitis C on HIV-1 disease progression. HIV Clin Trials 5:125-131.
10. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Ceron D, Degott C, Cacoub P, Perronne C (2004) Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 292:2839-2848.
11. Cheung RC, Currie S, Shen H, Ho SB, Bini EJ, Anand BS, Brau N, Wright TL (2005) Chronic hepatitis C in Latinos: natural history, treatment eligibility, acceptance, and outcomes. Am J Gastroenterol 100:2186-2193.
12. Committee on Crossing the Quality Chasm: Adaptation to Mental Health and Addictive Disorders (2006) A framework for improving quality, in Improving the Quality of Health Care for Mental and Substance-Use Conditions, pp 56-76. Institute of Medicine, National Academy Press, Washington, DC.
13. Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M, Matheron S, Le Moing V, Vachon F, Degott C, Valla D, Marcellin P (2001) The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 34:1193-1199.
14. Edlin BR (2002) Prevention and treatment of hepatitis C in injection drug users. Hepatology 36 (Suppl 1): S210-S219.
15. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ (2002) Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 136:288-292.
16. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D (2003) Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 36:97-100.
17. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state" A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198.
18. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr., Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982.
19. Galvan FH, Bing EG, Fleishman JA, London AS, Caetano R, Burnam MA, Longshore D, Morton SC, Orlando M, Shapiro M (2002) The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV Cost and Services Utilization Study. J Stud Alcohol 63:179-186.
20. Hadziyannis SJ, Sette H Jr., Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr., Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140:346-355.
21. Harris DR, Gonin R, Alter HJ, Wright EC, Buskell ZJ, Hollinger FB, Seeff LB (2001) The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med 134:120-124.
22. Hezode C, Lonjon I, Roudot-Thoraval F, Pawlotsky JM, Zafrani ES, Dhumeaux D (2003) Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study. Aliment Pharmacol Ther 17:1031-1037.
23. Johnson ME, Fisher DG, Fenaughty A, Theno SA (1998) Hepatitis C virus and depression in drug users. Am J Gastroenterol 93:785-789.
24. Kraus MR, Schafer A, Csef H, Faller H, Mork H, Scheurlen M (2001) Compliance with therapy in patients with chronic hepatitis C: associations with psychiatric symptoms, interpersonal problems, and mode of acquisition. Dig Dis Sci 46:2060-2065.
25. Loftis JM, Hauser P (2004) The phenomenology and treatment of interferon-induced depression. J Affect Disord 82:175-190.
26. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965.
27. Mayfield D, McLeod G, Hall P (1974) The CAGE questionnaire: validation of a new alcoholism screening instrument. Am J Psychiatry 131:1121-1123.
28. Mochida S, Ohnishi K, Matsuo S, Kakihara K, Fujiwara K (1996) Effect of alcohol intake on the efficacy of interferon therapy in patients with chronic hepatitis C as evaluated by multivariate logistic regression analysis. Alcohol Clin Exp Res 20 (suppl):371A-377A.
29. National Academy of Sciences (2006) Improving the quality of health care for mental and substance-use conditions, in Quality Chasm Series. National Academies of Science.
30. Ohnishi K, Matsuo S, Matsutani K, Itahashi M, Kakihara K, Suzuki K, Ito S, Fujiwara K (1996) Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 91:1374-1379.
31. Okazaki T, Yoshihara H, Suzuki K, Yamada Y, Tsujimura T, Kawano K, Abe H (1994) Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers. Scand J Gastroenterol 29:1039-1043.
32. Peters MG, Terrault NA (2002) Alcohol use and hepatitis C. Hepatology 36 (suppl 1): S220-S225.
33. Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349:825-832.
34. Restrepo A, Johnson TC, Widjaja D, Yarmus L, Meyer K, Clain DJ, Bodenheimer HC Jr, Min AD (2005) The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical centre. J Viral Hepat 12:86-90.
35. Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, Farmer A, Jablenski A, Pickens R, Regier DA, Sartorius N, Towle LH (1988) The composite international diagnostic interview. An epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry 45:1069-1077.
36. Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, Kirk O, Phillips A, Ledergerber B, Lundgren J (2005) Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 192:992-1002.
37. Safdar K, Schiff ER (2004) Alcohol and hepatitis C. Semin Liver Dis 24:305-315.
38. Samet JH, Libman H, LaBelle C, Steger K, Lewis R, Craven DE, Freedberg KA (1995) A model clinic for the initial evaluation and establishment of primary care for persons infected with human immunodeficiency virus. Arch Intern Med 155:1629-1633.
39. Samet JH, Phillips SJ, Horton NJ, Traphagen ET, Freedberg KA (2004) Detecting alcohol problems in HIV-infected patients: use of the CAGE questionnaire. AIDS Res Hum Retroviruses 20:151-155.
40. Schaefer M, Heinz A, Backmund M (2004) Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction 99:1167-1175.
41. Sherman KE, Rouster SD, Chung RT, Rajicic N (2002) Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS clinical trials group. Clin Infect Dis 34:831-837.
42. Smith K, Horton N, Saitz R, Samet J (2006) Use of mini-mental state examination in clinical substance use research studies. Drug Alcohol Depend 82:231-237.
43. Sobell LC, Cellucci T, Nirenberg TD, Sobell MB (1982) Do quantity-frequency data underestimate drinking-related health risks? Am J Public Health 72:823-828.
44. Sobell LC, Toneatto T, Sobell MB, Leo GI, Johnson L (1992) Alcohol abusers' perceptions of the accuracy of their self-reports of drinking: implications for treatment. Addict Behav 17:507-511.
45. Sylvestre DL (2002) Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 67:117-123.
46. Sylvestre DL (2005a) Approaching treatment for hepatitis C virus infection in substance users. Clin Infect Dis 41 (suppl 1): S79-S82.
47. Sylvestre DL (2005b) Treating hepatitis C virus infection in active substance users. Clin Infect Dis 40 (suppl 5): S321-S324.
48. Tabone M, Sidoli L, Laudi C, Pellegrino S, Rocca G, Della Monica P, Fracchia M, Galatola G, Molinaro GC, Arico S, Pera A (2002) Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy. J Viral Hepat 9:288-294.
49. Taylor LE (2005) Delivering care to injection drug users coinfected with HIV and hepatitis C virus. Clin Infect Dis 40 (suppl 5): S355-S361.
50. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT (2004) Peginterferon Alfa2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 351:438-450.